Abstract
AbstractImmunotherapies offer the potential to reprogramme the immune system to halt autoimmune destruction of insulin‐producing β‐cells within the pancreas, dealing with the root cause of type 1 diabetes (T1DM) for the first time. Leading on from this, teplizumab, the first drug in this class, has been found to delay the onset of T1DM by an average of three years in people stratified high risk for developing T1DM. This review will critically consider the evidence basis underlying the utility of teplizumab in the management of T1DM. Copyright © 2023 John Wiley & Sons.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
